DENALI THERAPEUTICS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 14.96 USD | -3.86% |
|
-9.88% | -30.29% |
| Apr. 09 | UBS Adjusts Denali Therapeutics Price Target to $32 From $70, Maintains Buy Rating | MT |
| Apr. 03 | Denali Therapeutics Insider Sold Shares Worth $1,896,250, According to a Recent SEC Filing | MT |
Financials (USD)
| Sales 2024 * | 65.76M | Sales 2025 * | 121M | Capitalization | 2.13B |
|---|---|---|---|---|---|
| Net income 2024 * | -411M | Net income 2025 * | -442M | EV / Sales 2024 * | 11 x |
| Net cash position 2024 * | 1.41B | Net cash position 2025 * | 1.17B | EV / Sales 2025 * | 7.93 x |
| P/E ratio 2024 * |
-5.72
x | P/E ratio 2025 * |
-5.67
x | Employees | 445 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 86.18% |
More Fundamentals
* Assessed data
More news
Latest transcript on Denali Therapeutics Inc.
More recommendations
More press releases
More news
| 1 day | -3.86% | ||
| 1 week | -9.88% | ||
| Current month | -27.10% | ||
| 1 month | -24.71% | ||
| 3 months | -13.02% | ||
| 6 months | -23.83% | ||
| Current year | -30.29% |
1 week
14.56
16.80
1 month
14.5621.04
Current year
14.5623.52
1 year
14.5633.31
3 years
14.5679.70
5 years
12.3993.94
10 years
12.3293.94
| Managers | Title | Age | Since |
|---|---|---|---|
Alexander Schuth
FOU | Founder | 50 | 13-10-13 |
Ryan Watts
FOU | Founder | 48 | 13-10-13 |
Joe Lewcock
CTO | Chief Tech/Sci/R&D Officer | - | 19-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Vicki Sato
CHM | Chairman | 75 | 15-03-31 |
Jay Flatley
BRD | Director/Board Member | 71 | 15-03-31 |
David Schenkein
BRD | Director/Board Member | 66 | 15-03-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.31% | 0 M€ | 0.00% | - | |
| 0.31% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-25 | 14.96 | -3.86% | 1,140,532 |
| 24-04-24 | 15.56 | -3.41% | 944,425 |
| 24-04-23 | 16.11 | +0.75% | 1,080,081 |
| 24-04-22 | 15.99 | -0.06% | 3,056,993 |
| 24-04-19 | 16 | -3.61% | 1,479,992 |
Delayed Quote Nasdaq, April 25, 2024 at 04:00 pm EDT
More quotes
Denali Therapeutics Inc. is a biopharmaceutical company. The Company is focused on developing a portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases and lysosomal storage disease. The Company has a portfolio of both small molecule and biotherapeutic medicines, comprising seven product candidates in clinical development across seven indications as well as preclinical therapeutic candidates. Its three late-stage development programs include tividenofusp alfa (DNL310) for mucopolysaccharidosis II (MPS II); BIIB122/DNL151 (LRRK2 inhibitor) for Parkinsonâs disease; and DNL343 (eIF2B activator) for amyotrophic lateral sclerosis (ALS). SAR443820/DNL788 (RIPK1 inhibitor) is being evaluated in a Phase II study for multiple sclerosis (MS). In addition, it has a Phase I/II study of TAK-594/DNL593 for frontotemporal dementia-granulin (FTD-GRN) and a Phase I/II study of DNL126 for MPS IIIA (Sanfilippo syndrome).
Calendar
2024-05-01
- Q1 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
14.96
USD
Average target price
40.27
USD
Spread / Average Target
+169.16%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -30.29% | 2.13B | |
| -2.26% | 103B | |
| +1.41% | 95.71B | |
| +0.23% | 22.02B | |
| -17.84% | 20.9B | |
| -9.30% | 17.85B | |
| -42.83% | 16.21B | |
| -17.63% | 15.52B | |
| +4.55% | 13.86B | |
| +32.11% | 12.04B |
- Stock Market
- Equities
- DNLI Stock
